Low-dose TNX-102 SL targets sleep receptors for MDD, avoiding norcyclobenzaprine buildup and promising cleaner daytime tolerability in HORIZON trial.
Gregory Sullivan, MD
Advertisement
Articles by Gregory Sullivan, MD
Explore how TNX-102 SL aims to improve major depressive disorder by enhancing slow-wave sleep, as the HORIZON phase 2 trial tests nightly dosing.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease
2
Home-Based tDCS for Depression: Expanding Access to Neuromodulation Treatment
3
HLP003, Deuterated Psilocin, as an Adjunctive Therapy for Major Depressive Disorder
4
Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder
5